Phys.org September 4, 2024
In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, and an additional outbreak in Central Africa of clade I virus. A team of researchers in the US (United States Army Medical Research Institute of Infectious Diseases, industry, NIH, Boston University) tested mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred protection against challenge and further mitigated symptoms and disease duration. mRNA-1769 enhanced viral control and disease attenuation compared with MVA, highlighting the potential for mRNA vaccines to mitigate future pandemic threats… read more. Open Access TECHNICAL ARTICLE
Graphical abstract. Credit: Cell, Volume 187, Issue 87, September 5, 2024Â